<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KETOPROFEN - ketoprofen capsule </strong><br><strong>KETOPROFEN - ketoprofen capsule, extended release </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_1f4acbdf-1d3f-428e-b02d-4c22c25582ed"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Cardiovascular Risk</span></p>
<ul>
<li> NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</li>
<li>Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</li>
</ul>
<p><span class="Bold">Gastrointestinal Risk</span></p>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</li></ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8a62d3d2-49db-4d6a-ba1e-1332a788ce01"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ketoprofen is a non-steroidal anti-inflammatory drug. The chemical name for ketoprofen is 2-(3-benzoylphenyl)-propionic acid with the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3180408-a3c0-4e02-8535-dea390a52277&amp;name=d90d411a-118c-428f-b365-89afffc6649a-01.jpg"></div>
<p>Its empirical formula is C<span class="Sub">16</span>H<span class="Sub">14</span>O<span class="Sub">3</span>, with a molecular weight of 254.29. It has a pKa of 5.94 in methanol:water (3:1) and an n-octanol:water partition coefficient of 0.97 (buffer pH 7.4).</p>
<p>Ketoprofen is a white or off-white, odorless, nonhygroscopic, fine to granular powder, melting at about 95°C. It is freely soluble in ethanol, chloroform, acetone, ether and soluble in benzene and strong alkali, but practically insoluble in water at 20°C.</p>
<p>Each ketoprofen immediate-release capsule for oral administration contains 50 mg or 75 mg of ketoprofen, USP. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate. In addition, each of the empty gelatin capsules contains gelatin and titanium dioxide and the following colorant agents:</p>
<p> 50 mg - D&amp;C Yellow No. 10, FD&amp;C Blue No.1 and FD&amp;C Yellow No. 6 </p>
<p> 75 mg - FD&amp;C Blue No.1 and FD&amp;C Green No. 3.</p>
<p> The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No.10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
<p> Each ketoprofen extended-release capsule, USP for oral administration contains 200 mg of ketoprofen, USP. In addition, each capsule contains the following inactive ingredients: ammonium hydroxide, colloidal anhydrous silica, dibutyl sebacate, ethylcellulose, hypromellose, maltodextrin, methacrylic acid copolymer type B, oleic acid, polyacrylate dispersion, silicon dioxide, sugar spheres, talc, triacetin and triethyl citrate.</p>
<p> In addition, each of the empty gelatin capsules contains gelatin, sodium lauryl sulfate, and titanium dioxide and the following colorant agents:</p>
<p>black iron oxide<br>FD&amp;C Blue No. 2<br> yellow iron oxide.</p>
<p> The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No.10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_d437edaa-358b-47a5-b20a-c4a1fdf804aa"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Ketoprofen is a non-steroidal anti-inflammatory drug with analgesic and antipyretic properties.</p>
<p>The anti-inflammatory, analgesic, and antipyretic properties of ketoprofen have been demonstrated in classical animal and <span class="Italics">in vitro</span> test systems. In anti-inflammatory models ketoprofen has been shown to have inhibitory effects on prostaglandin and leukotriene synthesis, to have antibradykinin activity, as well as to have lysosomal membrane-stabilizing action. However, its mode of action, like that of other non-steroidal anti-inflammatory drugs, is not fully understood.</p>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_51fb4baf-18d1-4f7f-8309-3c9a3ccd7709"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Ketoprofen is a racemate with only the S enantiomer possessing pharmacological activity. The enantiomers have similar concentration time curves and do not appear to interact with one another.</p>
<p>An <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>-concentration relationship for ketoprofen was established in an oral surgery <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> study with ketoprofen immediate-release capsules. The effect-site rate constant (K<span class="Sub">e0</span>) was estimated to be 0.9 hour<span class="Sup">-1</span> (95% confidence limits: 0 to 2.1), and the concentration (Ce<span class="Sub">50</span>) of ketoprofen that produced one-half the maximum PID (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference) was 0.3 mcg/mL (95% confidence limits: 0.1 to 0.5). Thirty-three (33) to 68% of patients had an onset of action (as measured by reporting some <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief) within 30 minutes following a single oral dose in <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> studies. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> relief (as measured by remedication) persisted for up to 6 hours in 26% to 72% of patients in these studies.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_8ff39ce9-b6bb-4356-b72b-e8f41f06ee29"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6afc5a37-39c0-4e9b-81ff-871f54363ac8"></a><a name="section-2.2.1"></a><p></p>
<h3>General</h3>
<p class="First">Ketoprofen immediate-release capsules and ketoprofen extended-release capsules both contain ketoprofen. They differ only in their release characteristics. Ketoprofen immediate-release capsules release drug in the stomach whereas ketoprofen extended-release capsules are designed to resist dissolution in the low pH of gastric fluid but release drug at a controlled rate in the higher pH environment of the small intestine (see <a href="#i4i_description_id_8a62d3d2-49db-4d6a-ba1e-1332a788ce01">DESCRIPTION</a>).</p>
<p>Irrespective of the pattern of release, the systemic availability (F<span class="Sub">s</span>) when either oral formulation is compared with IV administration is approximately 90% in humans. For 75 mg to 200 mg single doses, the area under the curve has been shown to be dose proportional. The figure depicts the plasma time curves associated with both products.</p>
<p>Ketoprofen is &gt; 99% bound to plasma proteins, mainly to albumin. </p>
<p>Separate sections follow which delineate differences between ketoprofen immediate-release capsules and ketoprofen extended-release capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d41354b8-3018-4e66-9670-985d2047bb7c"></a><a name="section-2.2.2"></a><p></p>
<h3>Absorption</h3>
<p class="First">Ketoprofen immediate-release capsules are rapidly and well absorbed, with peak plasma levels occurring within 0.5 to 2 hours.</p>
<p>Ketoprofen extended-release capsules are also well absorbed from this dosage form, although an observable increase in plasma levels does not occur until approximately 2 to 3 hours after taking the formulation. Peak plasma levels are usually reached 6 to 7 hours after dosing. (See Figure and <a href="#id_93aa1f37-d575-43b6-89a1-3fb31467b706">Table</a>, below). </p>
<p>When ketoprofen is administered with food, its total bioavailability (AUC) is not altered; however, the rate of absorption from either dosage form is slowed. </p>
<p>Ketoprofen immediate-release capsules – Food intake reduces C<span class="Sub">max</span> by approximately one-half and increases the mean time to peak concentration (t<span class="Sub">max</span>) from 1.2 hours for fasting subjects (range, 0.5 to 3 hours) to 2 hours for fed subjects (range, 0.75 to 3 hours). The fluctuation of plasma peaks may also be influenced by circadian changes in the absorption process.</p>
<p>Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with absorption of ketoprofen immediate-release capsules.</p>
<p>Ketoprofen extended-release capsules – Administration of ketoprofen extended-release capsules with a high fat meal causes a delay of about 2 hours in reaching the C<span class="Sub">max</span>; neither the total bioavailability (AUC) nor the C<span class="Sub">max</span> is affected. Circardian changes in the absorption process have not been studied.</p>
<p>The administration of antacids or other drugs which may raise stomach pH would not be expected to change the rate or extent of absorption of ketoprofen extended-release capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00913f25-f533-4907-acee-d89ac3180980"></a><a name="section-2.2.3"></a><p></p>
<h3>Multiple Dosing</h3>
<p class="First">Steady-state concentrations of ketoprofen are attained within 24 hours after commencing treatment with ketoprofen immediate-release capsules or ketoprofen extended-release capsules. In studies with healthy male volunteers, trough levels at 24 hours following administration of ketoprofen 200 mg extended-release capsules were 0.4 mg/L compared with 0.07 mg/L at 24 hours following administration of ketoprofen 50 mg immediate-release capsules QID (12 hours), or 0.13 mg/L following administration of ketoprofen 75 mg immediate-release capsules TID for 12 hours. Thus, relative to the peak plasma concentration, the accumulation of ketoprofen after multiple doses of ketoprofen immediate-release capsules or ketoprofen extended-release capsules is minimal.</p>
<p>The figure below shows a reduction in peak height and area after the second 50 mg dose. This is probably due to a combination of food effects, circadian effects, and plasma sampling times. It is unclear to what extent each factor contributes to the loss of peak height and area.</p>
<p>The shaded area represents ± 1 standard deviation (S.D.) around the mean for ketoprofen immediate-release capsules or ketoprofen extended-release capsules.<br> </p>
<p>KETOPROFEN PLASMA CONCENTRATIONS IN SUBJECTS RECEIVING 200 MG OF KETOPROFEN EXTENDED-RELEASE CAPSULES ONCE A DAY (QD), OR 50 MG OF KETOPROFEN IMMEDIATE-RELEASE CAPSULES EVERY 4 HOURS FOR 16 HOURS<br><img alt="Ketoprofen Plasma Concentrations" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3180408-a3c0-4e02-8535-dea390a52277&amp;name=d90d411a-118c-428f-b365-89afffc6649a-02.jpg"></p>
<a name="id_93aa1f37-d575-43b6-89a1-3fb31467b706"></a><table width="866.000">
<caption><span>COMPARISON OF PHARMACOKINETIC PARAMETERS FOR KETOPROFEN IMMEDIATE-RELEASE CAPSULES AND KETOPROFEN EXTENDED-RELEASE CAPSULES</span></caption>
<col align="left" width="50.1%">
<col align="center" width="24.9%">
<col align="center" width="24.9%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="middle"><span class="Bold"> Kinetic Parameters</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Ketoprofen<br>Immediate-release<br>(4 × 50 mg)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Ketoprofen<br>Extended-release<br>(1 × 200 mg)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">Extent of oral absorption<br>(bioavailability) F<span class="Sub">s</span> (%)</td>
<td class="Toprule" align="center" valign="top">~ 90<br>
</td>
<td align="center" valign="top">~ 90<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Peak plasma levels C<span class="Sub">max</span> (mg/L)<br> Fasted<br> Fed</td>
<td align="center" valign="top">
<br>3.9 ± 1.3<br>2.4 ± 1</td>
<td align="center" valign="top">
<br>3.1 ± 1.2<br>3.4 ± 1.3</td>
</tr>
<tr>
<td align="left" valign="middle">Time to peak concentration t<span class="Sub">max</span> (h)<br> Fasted<br> Fed</td>
<td align="center" valign="top">
<br>1.2 ± 0.6<br>2 ± 0.8</td>
<td align="center" valign="top">
<br>6.8 ± 2.1<br>9.2 ± 2.6</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Area under plasma concentration-time</span></td></tr>
<tr>
<td align="left" valign="middle">curve AUC<span class="Sub">0–24h</span> (mg∙h/L)<br> Fasted<br> Fed</td>
<td align="center" valign="top">
<br>32.1 ± 7.2<br>36.6 ± 8.1</td>
<td align="center" valign="top">
<br>30.1 ± 7.9<br>31.3 ± 8.1</td>
</tr>
<tr>
<td align="left" valign="middle">Oral-dose clearance CL/F (L/h)</td>
<td align="center" valign="top">6.9± 0.8</td>
<td align="center" valign="top">6.8 ± 1.8</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Half-life t<span class="Sub">1/2</span> (h)<br> [See footnote ]</td>
<td class="Botrule" align="center" valign="top">2.1 ± 1.2</td>
<td class="Botrule" align="center" valign="top">5.4 ± 2.2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41496580-2526-4df5-8b39-b1ec0f88f53c"></a><a name="section-2.2.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">The metabolic fate of ketoprofen is glucuronide conjugation to form an unstable acyl-glucuronide. The glucuronic acid moiety can be converted back to the parent compound. Thus, the metabolite serves as a potential reservoir for parent drug, and this may be important in persons with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, whereby the conjugate may accumulate in the serum and undergo deconjugation back to the parent drug (see <a href="#i4i_section_id_727c8b96-ebee-42d4-828c-7f9c6b4fd344">CLINICAL PHARMACOLOGY: Special Populations: Renally Impaired</a>). The conjugates are reported to appear only in trace amounts in plasma in healthy adults, but are higher in elderly subjects – presumably because of reduced renal clearance. It has been demonstrated that in elderly subjects following multiple doses (50 mg every 6 h), the ratio of conjugated to parent ketoprofen AUC was 30% and 3%, respectively, for the S &amp; R enantiomers.</p>
<p>There are no known active metabolites of ketoprofen. Ketoprofen has been shown not to induce drug metabolizing enzymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bea8f878-932f-4cda-8482-756ffdec6d69"></a><a name="section-2.2.5"></a><p></p>
<h3>Elimination</h3>
<p class="First">The plasma clearance of ketoprofen is approximately 0.08 L/kg/h with a V<span class="Sub">d</span> of 0.1 L/kg after IV administration. The elimination half-life of ketoprofen has been reported to be 2.05 ± 0.58 h (Mean ± S.D.) following IV administration, from 2 to 4 h following administration of ketoprofen immediate-release capsules, and 5.4 ± 2.2 h after administration of ketoprofen 200 mg extended-release capsules. In cases of slow drug absorption, the elimination rate is dependent on the absorption rate and thus t<span class="Sub">1/2</span> relative to an IV dose appears prolonged.</p>
<p>After a single 200 mg dose of ketoprofen extended-release capsules, the plasma levels decline slowly, and average 0.4 mg/L after 24 hours (see Figure above).</p>
<p>In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite. </p>
<p>Enterohepatic recirculation of the drug has been postulated, although biliary levels have never been measured to confirm this.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da8e36b8-0397-4897-b559-219e2ddb60d5"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e027ca4-6a06-4840-9550-a11021f9a2c6"></a><a name="section-2.3.1"></a><p></p>
<h3>Elderly</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_32465568-c285-4f6b-9a54-b7f00c605a70"></a><a name="section-2.3.1.1"></a><p></p>
<h4>Clearance and unbound fraction</h4>
<p class="First">The plasma and renal clearance of ketoprofen is reduced in the elderly (mean age, 73 years) compared to a younger normal population (mean age, 27 years). Hence, ketoprofen peak concentration and AUC increase with increasing age. In addition, there is a corresponding increase in unbound fraction with increasing age. Data from one trial suggest that the increase is greater in women than in men. It has not been determined whether age related changes in absorption among the elderly contribute to the changes in bioavailability of ketoprofen (see <a href="#i4i_geriatric_use_id_947913c6-d649-417f-8b95-423ddcac35b4">PRECAUTIONS: Geriatric Use</a>).</p>
<p>Ketoprofen immediate-release capsules – In a study conducted with young and elderly men and women, results for subjects older than 75 years of age showed that free drug AUC increased by 40% and C<span class="Sub">max </span>increased by 60% as compared with estimates of the same parameters in young subjects (those younger than 35 years of age; see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE ADMINISTRATION</a>).</p>
<p>Also in the elderly, the ratio of intrinsic clearance/availability decreased by 35% and plasma half-life was prolonged by 26%. This reduction is thought to be due to a decrease in hepatic extraction associated with aging.</p>
<p>Ketoprofen extended-release capsules – The effects of age and gender on ketoprofen disposition were investigated in two small studies in which elderly male and female subjects received ketoprofen 200 mg extended-release capsules. The results were compared with those from another study conducted in healthy young men.</p>
<p>Compared to the younger subject group, the elimination half-life in the elderly was prolonged by 54% and total drug C<span class="Sub">max</span> and AUC were 40% and 70% higher, respectively. Plasma concentrations in the elderly after single doses and at steady-state were essentially the same. Thus, no drug accumulation occurs.</p>
<p>In comparison to younger subjects taking the ketoprofen immediate-release formulation, there was a decrease of 16% and 25% in total drug C<span class="Sub">max</span> and AUC, respectively, among the elderly. Free drug data are not available for ketoprofen extended-release capsules.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_727c8b96-ebee-42d4-828c-7f9c6b4fd344"></a><a name="section-2.3.2"></a><p></p>
<h3>Renally Impaired</h3>
<p class="First">Studies of the effects of renal function impairment have been small. They indicate a decrease in clearance in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. In 23 patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, free ketoprofen peak concentration was not significantly elevated, but free ketoprofen clearance was reduced from 15 L/kg/h for normal subjects to 7 L/kg/h in patients with mildly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, and to 4 L/kg/h in patients with moderately to severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The elimination t<span class="Sub">1/2</span> was prolonged from 1.6 hours in normal subjects to approximately 3 hours in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and to approximately 5 to 9 hours in patients with moderately to severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>No studies have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> taking ketoprofen extended-release capsules (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a34dd96-fe44-407c-8f09-4a2da8d3521f"></a><a name="section-2.3.3"></a><p></p>
<h3>Hepatically Impaired</h3>
<p class="First">For patients with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span>, no significant changes in the kinetic disposition of ketoprofen immediate-release capsules were observed relative to age-matched normal subjects: the plasma clearance of drug was 0.07 L/kg/h in 26 hepatically impaired patients. The elimination half-life was comparable to that observed for normal subjects. However, the unbound (biologically active) fraction was approximately doubled, probably due to <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> and high variability which was observed in the pharmacokinetics for cirrhotic patients. Therefore, these patients should be carefully monitored and daily doses of ketoprofen kept at the minimum providing the desired therapeutic effect.</p>
<p>No studies have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> taking ketoprofen extended-release capsules (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ed894897-9fc9-4a02-bd6d-60a8b17d1252"></a><a name="section-2.4"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_359672b4-eb87-4c0e-b28d-7b79dcb2fbf7"></a><a name="section-2.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></h3>
<p class="First">The efficacy of ketoprofen has been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>. Using standard assessments of therapeutic response, there were no detectable differences in effectiveness or in the incidence of adverse events in crossover comparison of ketoprofen immediate-release capsules and ketoprofen extended-release capsules. In other trials, ketoprofen demonstrated effectiveness comparable to aspirin, ibuprofen, naproxen, piroxicam, diclofenac and indomethacin. In some of these studies there were more dropouts due to gastrointestinal side effects among patients on ketoprofen than among patients on other NSAIDs.</p>
<p>In studies with patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, ketoprofen was administered in combination with gold salts, antimalarials, low dose methotrexate, d-penicillamine, and/or corticosteroids with results comparable to those seen with control non-steroidal drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10117d73-8086-4587-a04a-401b4588e09e"></a><a name="section-2.4.2"></a><p></p>
<h3>Management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></h3>
<p class="First">The effectiveness of ketoprofen immediate-release capsules as a general purpose analgesic has been studied in standard <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> models which have shown the effectiveness of doses of 25 mg to 150 mg. Doses of 25 mg were superior to placebo. Doses larger than 25 mg generally could not be shown to be significantly more effective, but there was a tendency toward faster onset and greater duration of action with 50 mg, and, in the case of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, a significantly greater effect overall with 75 mg. Doses greater than 50 mg to 75 mg did not have increased <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>. Studies in <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> have shown that ketoprofen immediate-release capsules in doses of 25 mg to 100 mg was comparable to 650 mg of acetaminophen with 60 mg of codeine, or 650 mg of acetaminophen with 10 mg of oxycodone. Ketoprofen tended to be somewhat slower in onset; peak <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief was about the same and the duration of the effect tended to be 1 to 2 hours longer, particularly with the higher doses of ketoprofen.</p>
<p>The use of ketoprofen extended-release capsules in patients with <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> is not recommended, since, in comparison to ketoprofen immediate-release capsules, ketoprofen extended-release capsules would be expected to have a delayed analgesic response due to its extended-release characteristics.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fec7cd52-4f79-45db-9ba0-d949bcfceb5a"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</p>
<p>Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</p>
<p>Ketoprofen extended-release capsules are not recommended for treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> because of its extended-release characteristics (see <a href="#i4i_pharmacokinetics_id_8ff39ce9-b6bb-4356-b72b-e8f41f06ee29">CLINICAL PHARMACOLOGY: Pharmacokinetics</a>).</p>
<p>Ketoprofen immediate-release capsules are indicated for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Ketoprofen immediate-release capsules are also indicated for treatment of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7ca6526c-5e2c-4927-bcfd-0c7fb92ee099"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ketoprofen.</p>
<p>Ketoprofen immediate-release capsules and ketoprofen extended-release capsules should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergictype reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to ketoprofen have been reported in such patients (see <a href="#i4i_section_id_6a2f77d9-07bb-418c-a72e-0bc082218393">WARNINGS: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a> and <a href="#i4i_section_id_0c656f4e-ffae-4e05-9523-f7d86039b150">PRECAUTIONS : General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a>).</p>
<p>Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd8ce38a-b093-4e3c-885e-43d557269762"></a><a name="section-5.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eda7ca80-266a-40d9-adbb-5466b73b0e08"></a><a name="section-5.1.1"></a><p></p>
<h3>Cardiovascular Thrombotic Events</h3>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <a href="#i4i_section_id_76612ecb-2ed9-43d4-97b0-94138e8f7ae2">WARNINGS: Gastrointestinal Effects</a>).</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <a href="#i4i_contraindications_id_7ca6526c-5e2c-4927-bcfd-0c7fb92ee099">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbe4e660-0d76-4efb-9a19-3db25c8adef3"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">NSAIDs, including ketoprofen immediate-release capsules and ketoprofen extended-release capsules, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ketoprofen immediate-release capsules and ketoprofen extended-release capsules, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3303ee0d-5e17-4e58-8a62-d8f0f5ad1f40"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> has been observed in approximately 2% of patients taking ketoprofen. Ketoprofen immediate-release capsules and ketoprofen extended-release capsules should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76612ecb-2ed9-43d4-97b0-94138e8f7ae2"></a><a name="section-5.2"></a><p></p>
<h2>Gastrointestinal Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b849c347-c3e3-43cb-9e1b-afd207f6fff6"></a><a name="section-5.2.1"></a><p></p>
<h3>Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h3>
<p class="First">NSAIDs, including ketoprofen immediate-release capsules and ketoprofen extended-release capsules, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. </p>
<p>NSAIDs should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. </p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3dae4eac-ffba-4204-9889-5ee6e8555784"></a><a name="section-5.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greater risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_714396d6-4a07-41ea-9e74-40824753069f"></a><a name="section-5.3.1"></a><p></p>
<h3>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h3>
<p class="First">No information is available from controlled clinical studies regarding the use of ketoprofen immediate-release capsules or ketoprofen extended-release capsules in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with ketoprofen immediate-release capsules or ketoprofen extended-release capsules is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If ketoprofen immediate-release capsules or ketoprofen extended-release capsules therapy must be initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a2f77d9-07bb-418c-a72e-0bc082218393"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to ketoprofen immediate-release capsules or ketoprofen extended-release capsules. Ketoprofen immediate-release capsules or ketoprofen extended-release capsules should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <a href="#i4i_contraindications_id_7ca6526c-5e2c-4927-bcfd-0c7fb92ee099">CONTRAINDICATIONS</a> and <a href="#i4i_section_id_0c656f4e-ffae-4e05-9523-f7d86039b150">PRECAUTIONS: General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a>). Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69c722db-12e1-4b90-9fe8-a736d3133b58"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including ketoprofen immediate-release capsules and ketoprofen extended-release capsules, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f15d11e6-1e4d-4dc7-9f13-bb60581795e0"></a><a name="section-5.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, Ketoprofen immediate-release capsules and ketoprofen extended-release capsules should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8e05d056-7124-43fb-805a-5d9d3246dde9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b12d1e26-4599-4283-afbb-15ab09b72bc8"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Ketoprofen immediate-release capsules and ketoprofen extended-release capsules cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
<p>If steroid dosage is reduced or eliminated during therapy, it should be reduced slowly and the patients observed closely for any evidence of adverse effects, including <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
<p>The pharmacological activity of ketoprofen immediate-release capsules and ketoprofen extended-release capsules in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
<p>Ketoprofen and other non-steroidal anti-inflammatory drugs cause <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> in mice and rats associated with chronic administration. Rare cases of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> or <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> have been reported in humans with ketoprofen since it has been marketed.</p>
<p>A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. In these patients, administration of a non-steroidal anti-inflammatory drug results in a dose dependent decrease in prostaglandin synthesis and, secondarily, in renal blood flow which may precipitate overt <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics, and the elderly. Discontinuation of non-steroidal anti-inflammatory drug therapy is typically followed by recovery to the pretreatment state.</p>
<p>Since ketoprofen is primarily eliminated by the kidneys and its pharmacokinetics are altered by <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#i4i_clinical_pharmacology_id_d437edaa-358b-47a5-b20a-c4a1fdf804aa">CLINICAL PHARMACOLOGY</a>), patients with significantly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> should be closely monitored, and a reduction of dosage should be anticipated to avoid accumulation of ketoprofen and/or its metabolites (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30363ceb-95c1-4bdc-be0d-08a6dda46b25"></a><a name="section-6.1.1"></a><p></p>
<h3>Hepatic Effects</h3>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ketoprofen immediate-release capsules and ketoprofen extended-release capsules. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported. </p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ketoprofen immediate-release capsules or ketoprofen extended-release capsules. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), ketoprofen immediate-release capsules or ketoprofen extended-release capsules should be discontinued.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> with reduced serum albumin levels, ketoprofen's pharmacokinetics are altered (see <a href="#i4i_clinical_pharmacology_id_d437edaa-358b-47a5-b20a-c4a1fdf804aa">CLINICAL PHARMACOLOGY</a>). Such patients should be closely monitored, and a reduction of dosage should be anticipated to avoid high blood levels of ketoprofen and/or its metabolites (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c3c0735-35a7-4798-8d3a-0f1fd8f4f009"></a><a name="section-6.1.2"></a><p></p>
<h3>Hematological Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including ketoprofen immediate-release capsules and ketoprofen extended-release capsules. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ketoprofen immediate-release capsules or ketoprofen extended-release capsules, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. </p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ketoprofen immediate-release capsules or ketoprofen extended-release capsules who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c656f4e-ffae-4e05-9523-f7d86039b150"></a><a name="section-6.1.3"></a><p></p>
<h3>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross-reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, ketoprofen immediate-release capsules or ketoprofen extended-release capsules should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_de6e6fec-c2ec-40c4-9c13-20c813728b2c"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="Bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</span></p>
<ol>
<li>Ketoprofen immediate-release capsules or ketoprofen extended-release capsules, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_section_id_bd8ce38a-b093-4e3c-885e-43d557269762">WARNINGS: Cardiovascular Effects</a>).</li>
<li> Ketoprofen immediate-release capsules and ketoprofen extended-release capsules, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and rarely serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_section_id_b849c347-c3e3-43cb-9e1b-afd207f6fff6">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a>).</li>
<li>Ketoprofen immediate-release capsules and ketoprofen extended-release capsules, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</li>
<li>In late pregnancy, as with other NSAIDs, ketoprofen immediate-release capsules and ketoprofen extended-release capsules should be avoided because it may cause premature closure of the ductus arteriosus.</li>
</ol>
<p>NSAIDs are often essential agents in the management of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> and have a major role in the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, but they also may be commonly employed for conditions which are less serious. Physicians may wish to discuss with their patients the potential risks (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>, <a href="#i4i_precautions_general_id_b12d1e26-4599-4283-afbb-15ab09b72bc8">PRECAUTIONS: General</a> and <a href="#i4i_adverse_effects_id_3016737e-fe6f-47cb-8aab-da44db1b31b5">ADVERSE REACTIONS</a>) and likely benefits of NSAID treatment, particularly when the drugs are used for less serious conditions where treatment without NSAIDs may represent an acceptable alternative to both the patient and physician.</p>
<p>Because aspirin causes an increase in the level of unbound ketoprofen, patients should be advised not to take aspirin while taking ketoprofen (see <a href="#i4i_interactions_id_170c6eb3-5564-480a-9e68-c4635485b663">PRECAUTIONS: Drug Interactions</a>). It is possible that minor adverse symptoms of gastric intolerance may be prevented by administering ketoprofen immediate-release capsules with antacids, food or milk. Ketoprofen extended-release capsules have not been studied with antacids. Because food and milk do affect the rate but not the extent of absorption (see <a href="#i4i_clinical_pharmacology_id_d437edaa-358b-47a5-b20a-c4a1fdf804aa">CLINICAL PHARMACOLOGY</a>), physicians may want to make specific recommendations to patients about when they should take ketoprofen in relation to food and/or what patients should do if they experience minor GI symptoms associated with ketoprofen therapy.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_10931ef6-04d8-423b-bbfd-22aa53b686b0"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, ketoprofen immediate-release capsules and ketoprofen extended-release capsules should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_170c6eb3-5564-480a-9e68-c4635485b663"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7809400-eea8-4b9a-93c8-88ad6630632f"></a><a name="section-6.4.1"></a><p></p>
<h3>ACE Inhibitors</h3>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c41e59be-89d2-4c99-85f3-64eeea7b99ac"></a><a name="section-6.4.2"></a><p></p>
<h3>Antacids</h3>
<p class="First">Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_753b0260-c4e6-4429-a68a-6a627623394b"></a><a name="section-6.4.3"></a><p></p>
<h3>Aspirin</h3>
<p class="First">Ketoprofen does not alter aspirin absorption; however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin. The clinical significance of these changes is not known; however, as with other NSAIDs, concomitant administration of ketoprofen and aspirin is not generally recommended because of the potential of increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7919493-7881-4823-90ca-a430ee034427"></a><a name="section-6.4.4"></a><p></p>
<h3>Diuretics</h3>
<p class="First">NSAIDs can reduce the natriuetic effect of furosemide and thiazides in some patients. Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. Patients taking diuretics are at a greater risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to a decrease in renal blood flow caused by prostaglandin inhibition (see <a href="#i4i_precautions_id_8e05d056-7124-43fb-805a-5d9d3246dde9">PRECAUTIONS</a>). During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#i4i_section_id_3dae4eac-ffba-4204-9889-5ee6e8555784">WARNINGS: Renal Effects</a>), as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92bed3c9-78de-4e11-8e52-5c9a43a1b42d"></a><a name="section-6.4.5"></a><p></p>
<h3>Digoxin</h3>
<p class="First">In a study in 12 patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1be7b099-449f-4d39-b5ea-bb886d4101fb"></a><a name="section-6.4.6"></a><p></p>
<h3>Lithium</h3>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24ecbf01-a52d-4153-be5c-f6eb6315a50a"></a><a name="section-6.4.7"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity. NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fa0c45c-6f7e-405e-907d-7fe7a4fdcb96"></a><a name="section-6.4.8"></a><p></p>
<h3>Probenecid</h3>
<p class="First">Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding. Therefore, the combination of ketoprofen and probenecid is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df4ca3b1-fc4a-439a-8214-dfce23e8b7b9"></a><a name="section-6.4.9"></a><p></p>
<h3>Warfarin</h3>
<p class="First">The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone. In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> from a number of sites may be a complication of warfarin treatment and GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> a complication of ketoprofen treatment. Because prostaglandins play an important role in hemostasis and ketoprofen has an effect on platelet function as well (see <a href="#i4i_section_id_3ff60338-fa86-4e8b-9530-af9676dd477b">PRECAUTIONS: Drug/Laboratory Test Interactions: Effect on Blood Coagulation</a>), concurrent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_eb7982f2-e2d4-46c8-ac9c-6cfefb155999"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ff60338-fa86-4e8b-9530-af9676dd477b"></a><a name="section-6.5.1"></a><p></p>
<h3>Effect on Blood Coagulation</h3>
<p class="First">Ketoprofen decreases platelet <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> and aggregation. Therefore, it can prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> by approximately 3 to 4 minutes from baseline values. There is no significant change in platelet count, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, or <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e0485718-dde8-4fd6-8249-a08b18ae43ba"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Chronic oral toxicity studies in mice (up to 32 mg/kg/day; 96 mg/m<span class="Sup">2</span>/day) did not indicate a carcinogenic potential for ketoprofen. The maximum recommended human therapeutic dose is 300 mg/day for a 60 kg patient with a body surface area of 1.6 m<span class="Sup">2</span>, which is 5 mg/kg/day or 185 mg/m<span class="Sup">2</span>/day. Thus, the mice were treated at 0.5 times the maximum human daily dose based on surface area.</p>
<p>A 2 year carcinogenicity study in rats, using doses up to 6 mg/kg/day (36 mg/m<span class="Sup">2</span>/day), showed no evidence of tumorigenic potential. All groups were treated for 104 weeks except the females receiving 6 mg/kg/day (36 mg/m<span class="Sup">2</span>/day) where the drug treatment was terminated in week 81 because of low survival; the remaining rats were sacrificed after week 87. Their survival in the groups treated for 104 weeks was within 6% of the control group. An earlier 2 year study with doses up to 12.5 mg/kg/day (75 mg/m<span class="Sup">2</span>/day) also showed no evidence of tumorigenicity, but the survival rate was low and the study was therefore judged inconclusive. Ketoprofen did not show mutagenic potential in the Ames Test. Ketoprofen administered to male rats (up to 9 mg/kg/day; or 54 mg/m<span class="Sup">2</span>/day) had no significant effect on reproductive performance or fertility. In female rats administered 6 or 9 mg/kg/day (36 or 54 mg/m<span class="Sup">2</span>/day), a decrease in the number of implantation sites has been noted. The dosages of 36 mg/m<span class="Sup">2</span>/day in rats represent 0.2 times the maximum recommended human dose of 185 mg/m<span class="Sup">2</span>/day (see above).</p>
<p>Abnormal spermatogenesis or inhibition of spermatogenesis developed in rats and dogs at high doses, and a decrease in the weight of the testes occurred in dogs and baboons at high doses.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_82457b6d-7fdb-40c8-801c-3af9cf69e7b3"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_728714f8-c5bb-40fb-afbb-5aa1e63f81cd"></a><a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2e6a1b4-835a-4f9e-9181-8ddcb7c3db00"></a><a name="section-6.7.2"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">In teratology studies, ketoprofen administered to mice at doses up to 12 mg/kg/day (36 mg/m<span class="Sup">2</span>/day) and rats at doses up to 9 mg/kg/day (54 mg/m<span class="Sup">2</span>/day), the approximate equivalent of 0.2 times the maximum recommended therapeutic dose of 185 mg/m<span class="Sup">2</span>/day, showed no teratogenic or embryotoxic effects. In separate studies in rabbits, maternally toxic doses were associated with embryotoxicity but not <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women. <span class="Underline">Ketoprofen immediate-release capsules and ketoprofen extended-release capsules should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</span></p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_76fff482-8d0f-4914-95f2-099b4f3eb62a"></a><a name="section-6.7.3"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_036fd890-aa12-49d0-aea0-af5b75087848"></a><a name="section-6.8"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effects of ketoprofen on labor and delivery in pregnant women are unknown. Studies in rats have shown ketoprofen at doses of 6 mg/kg (36 mg/m<span class="Sup">2</span>/day, approximately equal to 0.2 times the maximum recommended human dose) prolongs pregnancy when given before the onset of labor. Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), use of ketoprofen during late pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_385fa915-649d-4414-98b0-7816af7f8277"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Data on secretion in human milk after ingestion of ketoprofen do not exist. In rats, ketoprofen at doses of 9 mg/kg (54 mg/m<span class="Sup">2</span>/day; approximately 0.3 times the maximum human therapeutic dose) did not affect perinatal development. Upon administration to lactating dogs, the milk concentration of ketoprofen was found to be 4% to 5% of the plasma drug level. As with other drugs that are excreted in milk, ketoprofen is not recommended for use in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ed79a545-ed9b-4083-81ec-d67e81788ea2"></a><a name="section-6.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 18 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_947913c6-d649-417f-8b95-423ddcac35b4"></a><a name="section-6.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older). In pharmacokinetic studies, ketoprofen clearance was reduced in older patients receiving ketoprofen immediate-release capsules or ketoprofen extended-release capsules, compared with younger patients. Peak ketoprofen concentrations and free drug AUC were increased in older patients (see <a href="#i4i_section_id_da8e36b8-0397-4897-b559-219e2ddb60d5">PHARMACOKINETICS: Special Populations</a>). The glucuronide conjugate of ketoprofen, which can serve as a potential reservoir for the parent drug, is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. It is recommended that the initial dosage of ketoprofen immediate-release capsules or ketoprofen extended-release capsules should be reduced for patients over 75 years of age and it may be useful to monitor renal function (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>). In addition, the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Elderly patients may be more sensitive to the antiprostaglandin effects of NSAIDS (on the gastrointestinal tract and kidneys) than younger patients (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a> and <a href="#i4i_precautions_id_8e05d056-7124-43fb-805a-5d9d3246dde9">PRECAUTIONS</a>). In particular, elderly or debilitated patients who receive NSAID therapy seem to tolerate gastrointestinal ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well than other individuals, and most spontaneous reports of fatal GI events are in this population. Therefore, caution should be exercised in treating the elderly, and when individualizing their dosage, extra care should be taken when increasing the dose (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>).</p>
<p>In ketoprofen immediate-release capsules clinical studies involving a total of 1,540 <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients, 369 (24%) were ≥ 65 years of age, and 92 (6%) were ≥ 75 years of age. For ketoprofen immediate-release capsules <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> studies, 23 (5%) of 484 patients were ≥ 60 years of age. In ketoprofen extended-release capsules clinical studies, 356 (42%) of 840 <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients were ≥ 65 years of age, and less than 100 of these were ≥ 75 years of age. No overall differences in effectiveness were observed between these patients and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_3016737e-fe6f-47cb-8aab-da44db1b31b5"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The incidence of common adverse reactions (above 1%) was obtained from a population of 835 ketoprofen immediate-release capsules treated patients in double-blind trials lasting from 4 to 54 weeks and in 622 ketoprofen extended-release capsules treated (200 mg/day) patients in trials lasting from 4 to 16 weeks.</p>
<p>Minor gastrointestinal side effects predominated; <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">upper gastrointestinal symptoms</span> were more common than lower <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>. In crossover trials in 321 patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> or <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, there was no difference in either upper or lower <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> between patients treated with 200 mg of ketoprofen extended-release capsules once a day or 75 mg of ketoprofen immediate-release capsules TID (225 mg/day). <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurred in controlled clinical trials in less than 1% of 1,076 patients; however, in open label continuation studies in 1,292 patients the rate was greater than 2%.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> in patients on NSAIDs is dependent on many risk factors including age, sex, smoking, alcohol use, diet, stress, concomitant drugs such as aspirin and corticosteroids, as well as the dose and duration of treatment with NSAIDs (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>).</p>
<p>Gastrointestinal reactions were followed in frequency by central nervous system side effects, such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. The incidence of some adverse reactions appears to be dose related (see <a href="#i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7">DOSAGE AND ADMINISTRATION</a>). Rare adverse reactions (incidence less than 1%) were collected from one or more of the following sources: foreign reports to manufacturers and regulatory agencies, publications, U.S. clinical trials, and/or U.S. post-marketing spontaneous reports.</p>
<p>Reactions are listed below under body system, then by incidence or number of cases in decreasing incidence.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abbcd7dc-a70e-416c-92d7-437df8307356"></a><a name="section-7.1"></a><p></p>
<h2>Incidence Greater than 1% (Probable Causal Relationship)</h2>
<p class="First"><span class="Bold"><span class="Italics">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> (11%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, CNS inhibition (i.e., pooled reports of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, etc.) or excitation (i.e., <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, dreams, etc.)<span class="Sup">1</span>. </p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital:</span></span> Impairment of renal function (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, increased BUN)<span class="Sup">1</span>, signs or symptoms of urinary-tract irritation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e484c6c8-7e42-460b-abbe-ea0022554eab"></a><a name="section-7.2"></a><p></p>
<h2>Incidence Less than 1% (Probable Causal Relationship)</h2>
<p class="First"><span class="Bold"><span class="Italics">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, vasodilation.</p>
<p><span class="Bold"><span class="Italics">Digestive:</span></span> Appetite increased, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, fecal occult blood, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span>, hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
<p><span class="Bold"><span class="Italics">Hemic:</span></span> Hypocoagulability, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional:</span></span> <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>. </p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory:</span></span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpuric rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rash</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4328079" conceptname="Onycholysis">onycholysis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> sicca, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, hearing impairment, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> change, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital:</span></span> <span class="product-label-link" type="condition" conceptid="4151132" conceptname="Menometrorrhagia">Menometrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9338c050-b0b3-4a30-8e72-03856434e6da"></a><a name="section-7.3"></a><p></p>
<h2>Incidence Less than 1% (Causal Relationship Unknown)</h2>
<p class="First">The following rare adverse reactions, whose causal relationship to ketoprofen is uncertain, are being listed to serve as alerting information to the physician.</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
<p><span class="Bold"><span class="Italics">Digestive:</span></span> Buccal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, microvesicular steatosis, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Endocrine:</span></span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus (aggravated).</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">Dysphoria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, libido disturbance, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital:</span></span> Acute tubulopathy, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ce440a8d-ee68-4ffa-b524-f3ef2266dc5f"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs and symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred following large ketoprofen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> may occur, but are rare.</p>
<p>Patients should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. Gut decontamination may be indicated in patients with symptoms seen within 4 hours (longer for sustained-release products) or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). This should be accomplished via <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and/or activated charcoal (60 g to 100 g in adults, 1 to 2 g/kg in children) with a saline cathartic or sorbitol added to the first dose. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of the urine, hemodialysis or hemoperfusion would probably not be useful due to ketoprofen's high protein binding.</p>
<p>Case reports include 26 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>: 6 were in children, 16 in adolescents, and 4 in adults. Five of these patients had minor symptoms (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 4, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in 1 child). A 12 year-old girl had tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span> 1 to 2 hours after ingesting an unknown quantity of ketoprofen and 1 or 2 tablets of acetaminophen with hydrocodone. Her ketoprofen level was 1128 mg/L (56 times the upper therapeutic level of 20 mg/L) 3 to 4 hours post ingestion. Full recovery ensued 18 hours after ingestion following management with intubation, diazepam, and activated charcoal. A 45 year-old woman ingested twelve 200 mg extended-release ketoprofen capsules and 375 mL vodka, was treated with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and supportive measures 2 hours after ingestion, and recovered completely with her only complaint being mild <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8dee2bad-7c24-4555-9372-e8ee3a04c4f7"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of a ketoprofen immediate-release capsules and ketoprofen extended-release capsules and other treatment options before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a>). </p>
<p>After observing the response to initial therapy with ketoprofen immediate-release capsules and ketoprofen extended-release capsules, the dose and frequency should be adjusted to suit an individual patient's needs.</p>
<p>Concomitant use of ketoprofen immediate-release capsules and ketoprofen extended-release capsules is not recommended.</p>
<p>If minor side effects appear, they may disappear at a lower dose which may still have an adequate therapeutic effect. If well tolerated but not optimally effective, the dosage may be increased. Individual patients may show a better response to 300 mg of ketoprofen immediate-release capsules daily as compared to 200 mg, although in well controlled clinical trials patients on 300 mg did not show greater mean effectiveness. They did, however, show an increased frequency of upper and lower GI distress and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. It is of interest that women also had an increased frequency of these adverse effects compared to men. When treating patients with 300 mg/day, the physician should observe sufficient increased clinical benefit to offset potential increased risk.</p>
<p>In patients with mildly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the maximum recommended total daily dose of ketoprofen immediate-release capsules or ketoprofen extended-release capsules is 150 mg. In patients with a more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR less than 25 mL/min/1.73 m<span class="Sup">2</span> or end-stage <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), the maximum total daily dose of ketoprofen immediate-release capsules or ketoprofen extended-release capsules should not exceed 100 mg.</p>
<p>In elderly patients, renal function may be reduced with apparently normal serum creatinine and/or BUN levels. Therefore, it is recommended that the initial dosage of ketoprofen immediate-release capsules or ketoprofen extended-release capsules should be reduced for patients over 75 years of age (see <a href="#i4i_geriatric_use_id_947913c6-d649-417f-8b95-423ddcac35b4">PRECAUTIONS: Geriatric Use</a>).</p>
<p>It is recommended that for patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> and serum albumin concentration less than 3.5 g/dL, the maximum initial total daily dose of ketoprofen immediate-release capsules or ketoprofen extended-release capsules should be 100 mg. All patients with metabolic impairment, particularly those with both <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> and reduced renal function, may have increased levels of free (biologically active) ketoprofen and should be closely monitored. The dosage may be increased to the range recommended for the general population, if necessary, only after good individual tolerance has been ascertained.</p>
<p>Because <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> and reduced renal function both increase the fraction of free drug (biologically active form), patients who have both conditions may be at greater risk of adverse effects. Therefore, it is recommended that such patients also be started on lower doses of ketoprofen immediate-release capsules or ketoprofen extended-release capsules and closely monitored.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d4cef28-ad93-44e6-b372-547f716c1616"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></h2>
<p class="First">The recommended starting dose of ketoprofen in otherwise healthy patients is for ketoprofen immediate-release capsules 75 mg three times or 50 mg four times a day, or for ketoprofen extended-release capsules 200 mg administered once a day. Smaller doses of ketoprofen immediate-release capsules or ketoprofen extended-release capsules should be utilized initially in small individuals, or in debilitated or elderly patients. The recommended maximum daily dose of ketoprofen is 300 mg/day for ketoprofen immediate-release capsules or 200 mg/day for ketoprofen extended-release capsules.</p>
<p>Dosages higher than 300 mg/day of ketoprofen immediate-release capsules or 200 mg/day of ketoprofen extended-release capsules are not recommended because they have not been studied. Concomitant use of ketoprofen immediate-release capsules and ketoprofen extended-release capsules is not recommended. Relatively smaller people may need smaller doses.</p>
<p>As with other non-steroidal anti-inflammatory drugs, the predominant adverse effects of ketoprofen are gastrointestinal. To attempt to minimize these effects, physicians may wish to prescribe that ketoprofen immediate-release capsules or ketoprofen extended-release capsules be taken with antacids, food, or milk. Although food delays the absorption of both formulations (see <a href="#i4i_clinical_pharmacology_id_d437edaa-358b-47a5-b20a-c4a1fdf804aa">CLINICAL PHARMACOLOGY</a>) in most of the clinical trials ketoprofen was taken with food or milk.</p>
<p>Physicians may want to make specific recommendations to patients about when they should take ketoprofen immediate-release capsules or ketoprofen extended-release capsules in relation to food and/or what patients should do if they experience minor GI symptoms associated with either formulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93a4f23e-b1b7-4aab-9652-0c436bef4f81"></a><a name="section-9.2"></a><p></p>
<h2>Management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></h2>
<p class="First">The usual dose of ketoprofen immediate-release capsules recommended for mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> is 25 to 50 mg every 6 to 8 hours as necessary. A smaller dose should be utilized initially in small individuals, in debilitated or elderly patients, or in patients with renal or liver disease (see <a href="#i4i_precautions_general_id_b12d1e26-4599-4283-afbb-15ab09b72bc8">PRECAUTIONS: General</a>). A larger dose may be tried if the patient's response to a previous dose was less than satisfactory, but doses above 75 mg have not been shown to give added <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Daily doses above 300 mg are not recommended because they have not been adequately studied. Because of its typical non-steroidal anti-inflammatory drug-side effect profile, including as its principal adverse effect GI side effects (see <a href="#i4i_warnings_id_1c1550c0-bc48-400d-b9b8-45e28ce9d0c9">WARNINGS</a> and <a href="#i4i_adverse_effects_id_3016737e-fe6f-47cb-8aab-da44db1b31b5">ADVERSE REACTIONS</a>), higher doses of ketoprofen immediate-release capsules should be used with caution and patients receiving them observed carefully.</p>
<p>Ketoprofen extended-release capsules are not recommended for use in treating <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> because of its extended-release characteristics.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a772b36f-6308-404b-8ea0-77398a1739d8"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ketoprofen Immediate-release Capsules are available containing 50 mg or 75 mg of ketoprofen, USP.</p>
<p>The 50 mg capsule is a hard-shell gelatin capsule with a light celery opaque cap and a light celery opaque body filled with a white to off-white powder. The capsule is axially printed with <span class="Bold">MYLAN </span>over<span class="Bold"> 4070</span> in black ink on both the body and cap. They are available as follows:</p>
<a name="i3670cb32-d249-4373-8627-0518d1039602"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>bottles of 30<br>
</td>
<td>NDC 54868-2414-0<br>
</td>
</tr></tbody></table>
<p></p>
<p>The 75 mg capsule is a hard-shell gelatin capsule with a light aqua opaque cap and a light aqua opaque body filled with a white to off-white powder. The capsule is axially printed with <span class="Bold">MYLAN </span>over <span class="Bold">5750 </span>in black ink on both the body and cap. They are available as follows:</p>
<a name="ic9e4d091-e11e-4c9c-83cc-dba3e3899295"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>bottles of 10<br>
</td>
<td>NDC 54868-2415-6<br>
</td>
</tr>
<tr>
<td>bottles of 30<br>
</td>
<td>NDC 54868-2415-2<br>
</td>
</tr>
<tr>
<td>bottles of 60<br>
</td>
<td>NDC 54868-2415-1<br>
</td>
</tr>
<tr class="Last">
<td>bottles of 100<br>
</td>
<td>NDC 54868-2415-4<br>
</td>
</tr>
</tbody></table>
<p>Ketoprofen Extended-release Capsules, USP are available containing 200 mg of ketoprofen, USP.</p>
<p>The 200 mg extended-release capsule is a hard-shell gelatin capsule with a blue green opaque cap and a iron gray opaque body axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">8200</span> in black ink on both the cap and body. They are available as follows:</p>
<a name="id5f1ad3f-7268-4e90-84e9-9582f4a89326"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>bottles of 30<br>
</td>
<td>NDC 54868-4826-0<br>
</td>
</tr>
<tr class="Last">
<td>bottles of 60<br>
</td>
<td>NDC 54868-4826-3<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from direct light and excessive heat and humidity.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Medication Guide with each prescription.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED FEBRUARY 2011<br>KETO:R9mc</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma         74146<br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_1c928107-24f4-4799-82c7-60c5c0ae7268"></a><a name="section-11"></a><p></p>
<h1>Medication Guide<br>for<br>Non-Steroidal Anti-Inflammatory Drugs<br>(NSAIDs)</h1>
<p class="First"><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This chance increases: </p>
<ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </span></p>
<ul>
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with: </span></p>
<ul>
<li>taking medicines called "corticosteroids" and "anticoagulants"</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used: </span></p>
<ul>
<li>exactly as prescribed </li>
<li>at the lowest dose possible for your treatment </li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as: </p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine: </span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li> for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li> about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist. </span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<a name="id_741f403a-a6c4-4175-8a99-5a9737545994"></a><table width="721.000">
<col align="left" width="50.2%">
<col align="left" width="49.8%">
<tbody class="Headless"><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Serious side effects include:<br></span><ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
</td>
<td class="Rrule" align="left" valign="top">
<span class="Bold">Other side effects include:</span><br><ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) </span></p>
<ul>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines. </li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<a name="id_6b2f687f-3d4a-4279-963f-0db46031faf7"></a><table width="865.000">
<caption><span>NSAID medicines that need a prescription</span></caption>
<col align="left" width="50.2%">
<col align="left" width="49.8%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Generic Name</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Tradename</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Celecoxib</td>
<td class="Rrule" align="left" valign="top">Celebrex</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diclofenac</td>
<td class="Rrule" align="left" valign="top">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diflunisal</td>
<td class="Rrule" align="left" valign="top">Dolobid</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Etodolac</td>
<td class="Rrule" align="left" valign="top">Lodine, Lodine XL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Fenoprofen</td>
<td class="Rrule" align="left" valign="top">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Flurbiprofen</td>
<td class="Rrule" align="left" valign="top">Ansaid</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Ibuprofen</td>
<td class="Rrule" align="left" valign="top">Motrin, Tab-Profen, Vicoprofen (combined with hydrocodone), Combunox (combined with oxycodone)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Indomethacin</td>
<td class="Rrule" align="left" valign="top">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Ketoprofen</td>
<td class="Rrule" align="left" valign="top">Oruvail</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Ketorolac</td>
<td class="Rrule" align="left" valign="top">Toradol</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Mefenamic Acid</td>
<td class="Rrule" align="left" valign="top">Ponstel</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Meloxicam</td>
<td class="Rrule" align="left" valign="top">Mobic</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Nabumetone</td>
<td class="Rrule" align="left" valign="top">Relafen</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Naproxen</td>
<td class="Rrule" align="left" valign="top">Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Oxaprozin</td>
<td class="Rrule" align="left" valign="top">Daypro</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Piroxicam</td>
<td class="Rrule" align="left" valign="top">Feldene</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Sulindac</td>
<td class="Rrule" align="left" valign="top">Clinoril</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Tolmetin</td>
<td class="Rrule" align="left" valign="top">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised 06/2009</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2757b969-401c-4e60-a460-4665b1f06608"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg</span></p>
<p><img alt="Ketoprofen Capsules 50 mg Bottles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3180408-a3c0-4e02-8535-dea390a52277&amp;name=2414.jpg"></p>
<p><span class="Bold">Ketoprofen</span><br><span class="Bold">Capsules</span><br><span class="Bold">50 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the Medication</span><br><span class="Bold">Guide provided separately to each patient.</span></p>
<p><span class="Bold">Rx only <br></span></p>
<p>Each capsule contains:<br>Ketoprofen, USP <span class="Bold">. . . . </span>50 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F ).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from direct light and</span><br><span class="Bold">excessive heat and humidity.</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_02c40191-d36b-492f-b8c1-1860e104d3a6"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 75 mg</span></p>
<p><img alt="Ketoprofen Capsules 75 mg Bottles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3180408-a3c0-4e02-8535-dea390a52277&amp;name=2415.jpg"></p>
<p><span class="Bold">Ketoprofen</span><br><span class="Bold">Capsules</span><br><span class="Bold">75 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the Medication</span><br><span class="Bold">Guide provided separately to each patient.</span></p>
<p><span class="Bold">Rx only <br></span></p>
<p>Each capsule contains:<br>Ketoprofen, USP <span class="Bold">. . . . </span>75 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F ).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from direct light and</span><br><span class="Bold">excessive heat and humidity.</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_65271e11-feda-4357-91c7-4eb1941308ef"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg</span></p>
<p><img alt="Ketoprofen Extended-release Capsules 200 mg Bottles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3180408-a3c0-4e02-8535-dea390a52277&amp;name=4826.jpg"></p>
<p><span class="Bold">Ketoprofen</span><br><span class="Bold">Extended-Release</span><br><span class="Bold">Capsules, USP</span><br><span class="Bold">200 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the Medication</span><br><span class="Bold">Guide provided separately to each patient.</span></p>
<p><span class="Bold">Rx only <br></span></p>
<p>Each capsule contains:<br>Ketoprofen, USP <span class="Bold">. . . . </span>200 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F ).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from direct light and</span><br><span class="Bold">excessive heat and humidity.</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOPROFEN 		
					</strong><br><span class="contentTableReg">ketoprofen capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2414(NDC:0378-4070)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>KETOPROFEN</strong> (KETOPROFEN) </td>
<td class="formItem">KETOPROFEN</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (Light celery opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;4070</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2414-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074035</td>
<td class="formItem">02/14/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOPROFEN 		
					</strong><br><span class="contentTableReg">ketoprofen capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2415(NDC:0378-5750)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>KETOPROFEN</strong> (KETOPROFEN) </td>
<td class="formItem">KETOPROFEN</td>
<td class="formItem">75 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C GREEN NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light aqua opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;5750</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2415-1</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-2415-2</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-2415-4</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-2415-6</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074035</td>
<td class="formItem">08/15/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOPROFEN 		
					</strong><br><span class="contentTableReg">ketoprofen capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4826(NDC:0378-8200)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>KETOPROFEN</strong> (KETOPROFEN) </td>
<td class="formItem">KETOPROFEN</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIBUTYL SEBACATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Blue/green opaque) , GRAY (Iron gray opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;8200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4826-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4826-3</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075679</td>
<td class="formItem">06/23/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b77c9d7d-6c4c-4716-b724-72e15b3ea4d2</div>
<div>Set id: b3180408-a3c0-4e02-8535-dea390a52277</div>
<div>Version: 7</div>
<div>Effective Time: 20120626</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
